BioLineRX
BLRX
31 hedge funds and large institutions have $2.42M invested in BioLineRX in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
63% more capital invested
Capital invested by funds: $1.49M → $2.42M (+$935K)
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
7% more funds holding
Funds holding: 29 → 31 (+2)
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
49% less call options, than puts
Call options by funds: $35K | Put options by funds: $69K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.31M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$547K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$107K |
| 4 |
AI
Atria Investments
Charlotte,
North Carolina
|
+$70.3K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$150K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$58.2K |
| 3 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$38.8K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$35.3K |
| 5 |
LPL Financial
San Diego,
California
|
-$12.3K |
BLRX Hedge Fund Activity: Q2 2024 in Review
31 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2024, worth a combined $2.42M — up 63% from $1.49M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BLRX positions and 4 closed out — a net gain of 3 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $1.31M. The largest seller was Morgan Stanley, cutting an estimated $150K.
- 31 institutional investors held BioLineRX (BLRX) as of Q2 2024, up from 29 in Q1 2024.
- Funds reported $2.42M of BioLineRX stock for Q2 2024, up 63% quarter-over-quarter.
- 7 funds opened new BioLineRX positions in Q2 2024 and 4 closed out, a net change of +3 holders.
- The largest BioLineRX buyer in Q2 2024 was Alyeska Investment Group, an estimated $1.31M added.
- The largest BioLineRX seller in Q2 2024 was Morgan Stanley, an estimated $150K sold.
Based on aggregated 13F filings for Q2 2024.